This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Messer, S. A.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Messer, S. A.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2009, p. 1942-1946, Vol. 47, No. 6
0095-1137/09/$08.00+0     doi:10.1128/JCM.02434-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007) {triangledown}

Shawn A. Messer,1* Gary J. Moet,1 Jeffrey T. Kirby,1 and Ronald N. Jones1,2

JMI Laboratories, North Liberty, Iowa,1 Tufts University School of Medicine, Boston, Massachusetts2

Received 18 December 2008/ Returned for modification 9 February 2009/ Accepted 9 April 2009

Results from the SENTRY international fungal surveillance program for 2006 to 2007 are presented. A total of 1,448 Candida sp., 49 Aspergillus fumigatus, and 33 Cryptococcus neoformans isolates were obtained from infected sterile-site sources in patients on five continents. Reference susceptibility was determined for anidulafungin, caspofungin, 5-flucytosine, fluconazole, itraconazole, posaconazole, voriconazole, and amphotericin B by CLSI methods.

* Corresponding author. Mailing address: Molecular Epidemiology and Fungus Testing Laboratory, Department of Pathology, University of Iowa, Iowa City, IA 52242. Phone: (319) 335-8172. Fax: (319) 335-6880. E-mail: messers{at}healthcare.uiowa.edu

{triangledown} Published ahead of print on 22 April 2009.

Journal of Clinical Microbiology, June 2009, p. 1942-1946, Vol. 47, No. 6
0095-1137/09/$08.00+0     doi:10.1128/JCM.02434-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Crandon, J. L., Banevicius, M. A., Fang, A. F., Crownover, P. H., Knauft, R. F., Pope, J. S., Russomanno, J. H., Shore, E., Nicolau, D. P., Kuti, J. L. (2009). Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. Antimicrob. Agents Chemother. 53: 5102-5107 [Abstract] [Full Text]  
  • Spreghini, E., Orlando, F., Santinelli, A., Pisa, E., Loretelli, C., Manso, E., Milici, M. E., Scalise, G., Barchiesi, F. (2009). Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus. Antimicrob. Agents Chemother. 53: 4035-4039 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»